Results 61 to 70 of about 13,388,827 (299)

Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data

BMC Medicine
Background Diabetes mellitus increases the risk of developing tuberculosis (TB) and negatively affects TB treatment outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in glycemic control but can also modulate immune pathways involved in immune ...
Yi-Geng Chen, James Cheng-Chung Wei, Fu-Shun Yen, Chen-Yu Sung, Yu-Han Huang, Teng-Shun Yu, Fuu-Jen Tsai, Chii-Min Hwu, Chih-Cheng Hsu   +8 more
doaj   +1 more source

An Avalanche Effect Nanomodulator Triggers Cascade Ferroptosis/Cuproptosis for Immunosuppressive Microenvironment Remodeling

Advanced Science, EarlyView.
A nanomodulator called L‐Arginine/lificiguat@Copper‐hollow Prussian blue@Calcium phosphate nanoparticles is constructed to launch a self‐amplifying “avalanche effect” in tumor cells. The ensuing cascade, triggered by the acidic tumor microenvironment and near‐infrared light, induces calcium overload, generates a reactive oxygen species and reactive ...
Hongmei Zhou, Caixi Yu, Guilan Xu, Lijuan Liu, Yujia Liang, Yulin Liang, He Ding, Litu Zhang, Piaoping Yang, Chen Wang   +9 more
wiley   +1 more source

DPP-4 inhibition protects human umbilical vein endothelial cells from hypoxia-induced vascular barrier impairment

Journal of Pharmacological Sciences, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are relatively new class of anti-diabetic drugs. Some protective effects of DPP-4 on cardiovascular disease have been described independently from glucose-lowering effect.
Naoko Hashimoto, Kento Ikuma, Yui Konno, Masanori Hirose, Hiroyuki Tadokoro, Hiroshi Hasegawa, Yoshio Kobayashi, Hiroyuki Takano   +7 more
doaj   +1 more source

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report

American Journal of Ophthalmology Case Reports, 2023
Purpose: To report a rare Ocular Cicatricial Pemphigoid (OCP) case in a patient taking a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), a medication used for the management of type 2 diabetes, for at least six years. Observations: A 64-year-old male
Akifumi Matsumoto, Hideki Fukuoka, Akiko Yoneda, Norihiko Yokoi, Chie Sotozono   +4 more
doaj   +1 more source

Dual‐line Genome‐scale CRISPR Screening Enables Robust Target Gene Discovery

Advanced Science, EarlyView.
A species‐optimized CRISPR platform integrates efficient piggyBac delivery, genome‐scale sgRNA libraries, and parallel screening in two independently engineered Bactrocera dorsalis Cas9 cell lines. Cross‐line consensus analysis filters line‐specific effects, enriches candidates with reproducible in vivo phenotypes, and reveals conserved, species ...
Ziniu Li, Jiao Qiao, Qiuyuan Zhang, Peipei Liu, Chenjun Zheng, Qi Zhou, Mengqi Ji, Zhihui Zhu, Xiaoxue Li, Hongyu Zhang   +9 more
wiley   +1 more source

Study on Anti-inflammatory and Anti-oxidative Stress Mechanism of Sitagliptin: a Dipeptidyl Peptidase-4 Inhibitor [PDF]

Zhongguo quanke yixue
The prevalence rate of type 2 diabetes is increasing year by year. It is known that oxidative stress and inflammation can participate in the occurrence and development of diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors can enhance the incretin effect
ZHU Jing, XIE Ji, HU Xiaoxia
doaj   +1 more source

DPP-4 activity.

, 2013
DPP-4 activity was measured 24 h after administration of the respective compounds (N = 13–17 per DPP-4 inhibitor group, control N = 57; no difference was made between sham-operated rats and 5/6N groups). All drugs showed a significant inhibition of DPP-4
Berthold Hocher (311916), Markus Alter (339018), Frank Runge (339021), Lyubov Chaykovska (339015), Holger Fuchs (339020), Susi Heiden (339019), Jan Rahnenführer (339017), Thomas Klein (121443), Karoline von Websky (311911)   +8 more
core   +1 more source

Disease‐Stage Synchronized Nanozyme Therapy for Polymicrobial Sepsis through Adaptive Catalytic and Immune Reprogramming

Advanced Science, EarlyView.
A disease‐stage synchronized nanozyme platform is developed to treat polymicrobial sepsis by adapting its functions to changing infection environments. The system eliminates multidrug‐resistant bacteria during early infection while reducing inflammation and restoring immune balance during recovery, providing an integrated strategy for infection control
Anlai Zou, Xiaoxue Zhu, Runhan Zhu, Chengchu Xue, Qinyu Zhang, Mengke Li, Ting Yu, Yuzhen Gao, Zhi Ruan, Ying Fu, Yunlei Xianyu, Jun Zhang   +11 more
wiley   +1 more source

Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats

Journal of Pharmacological Sciences, 2014
.: To clarify the role of dipeptidyl peptidase-4 (DPP-4) inhibition in vascular tissues, we compared the effects of the poorly tissue-penetrative DPP-4 inhibitor sitagliptin to the highly tissue-penetrative DPP-4 inhibitor linagliptin in Zucker diabetic ...
Shinji Takai, Hiroshi Sakonjo, Denan Jin
doaj   +1 more source

Asymmetric Synthesis of Highly Functionalized Tetrahydropyran DPP‑4 Inhibitor

, 2016
A practical synthesis of a highly functionalized tetrahydropyran DPP-4 inhibitor is described. The asymmetric synthesis relies on three back-to-back Ru-catalyzed reactions.
Yoshinori Kohmura (1734763), Mahbub Alam (734001), Jeremy Scott (1734766), Michael J. Zacuto (1734769), Feng Xu (89016), David Tschaen (1734760), Andrew Gibb (667403), Jon Rosen (1734772)   +7 more
core   +1 more source